Publicaciones en las que colabora con Ildefonso Espigado Tocino (13)

2024

  1. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

  2. Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

    Mediterranean Journal of Hematology and Infectious Diseases, Vol. 16, Núm. 1

2023

  1. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

2022

  1. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

    American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42

2021

  1. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group

    Transplant Infectious Disease, Vol. 23, Núm. 4

  2. Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment

    Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1281-1290

  3. Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group

    American Journal of Transplantation, Vol. 21, Núm. 1, pp. 258-271

2020

  1. Risk factors and outcome of COVID-19 in patients with hematological malignancies

    Experimental Hematology and Oncology, Vol. 9, Núm. 1

2017

  1. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial

    The Lancet Haematology, Vol. 4, Núm. 12, pp. e573-e583

  2. Posicionamiento y actitudes de manejo sobre la profilaxis antifúngica en el paciente hematológico (proyecto PROMIC)

    Revista Espanola de Quimioterapia, Vol. 30, Núm. 3, pp. 213-223

2015

  1. Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: Improving outcomes over time

    Bone Marrow Transplantation, Vol. 50, Núm. 2, pp. 274-281

2013

  1. To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors

    European Journal of Haematology, Vol. 91, Núm. 5, pp. 448-455

2011

  1. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients

    Haematologica, Vol. 96, Núm. 8, pp. 1231-1235